These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 33856296)

  • 1. Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding.
    Rech MA; Masic D; Hammond DA
    West J Emerg Med; 2021 Feb; 22(2):163-169. PubMed ID: 33856296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate.
    Lipari L; Yang S; Milligan B; Blunck J
    Am J Emerg Med; 2020 Dec; 38(12):2641-2645. PubMed ID: 33041150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
    Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA
    J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
    Sin JH; Berger K; Lesch CA
    J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
    Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI
    Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages.
    Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K
    Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of 4-Factor Prothrombin Complex Concentrate for Reversal of Oral Factor Xa Inhibitor-Associated Acute Major Bleeding: A Case Series.
    Reynolds TR; Gilbert BW; Hall KM
    J Pharm Pract; 2021 Oct; 34(5):755-760. PubMed ID: 32089040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa.
    Barton CA; Hom M; Johnson NB; Case J; Ran R; Schreiber M
    Am J Surg; 2018 May; 215(5):775-779. PubMed ID: 29338845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboembolic Risk of 4-Factor Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Urgent Warfarin Reversal in the Emergency Department.
    Maguire M; Fuh L; Goldstein JN; Marshall AL; Levine M; Howell ML; Parry BA; Rosovsky R; Hayes BD
    West J Emerg Med; 2019 Jul; 20(4):619-625. PubMed ID: 31316701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products.
    Castillo R; Chan A; Atallah S; Derry K; Baje M; Zimmermann LL; Martin R; Groysman L; Stern-Nezer S; Minokadeh A; Nova A; Huang W; Cang W; Schomer K
    J Thromb Thrombolysis; 2021 Jan; 51(1):151-158. PubMed ID: 32500220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Reversal of Factor Xa Inhibition in the Setting of Major Life-Threatening Bleeding or Urgent Surgery.
    Schmidt LE; Hinton MS; Martin ND
    J Pharm Pract; 2024 Feb; 37(1):74-79. PubMed ID: 36083782
    [No Abstract]   [Full Text] [Related]  

  • 12. Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor-associated bleeding: Case series.
    Liu J; Elsamadisi P; Philips E; Bauer KA; Eche IM
    Am J Health Syst Pharm; 2022 Aug; 79(16):1323-1329. PubMed ID: 35291008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative hemostatic efficacy of 4F-PCC in patients with intracranial hemorrhage on factor Xa inhibitors versus warfarin.
    Heath M; Hall B; De Leon J; Gillespie R; Hasara S; Henricks B; Lakshmi M; Watson D; Wilson K
    Am J Emerg Med; 2022 Jul; 57():149-152. PubMed ID: 35580546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin.
    Kuroski JE; Young S
    Am J Emerg Med; 2017 Jun; 35(6):871-874. PubMed ID: 28161220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.
    Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ
    J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation.
    Endres K; St Bernard R; Chin-Yee I; Hsia C; Lazo-Langner A
    Hematology; 2020 Dec; 25(1):489-493. PubMed ID: 33317427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and effectiveness of 4-factor prothrombin complex concentrate (4F-PCC) for warfarin and non-warfarin reversals.
    Santibanez M; Lesch CA; Lin L; Berger K
    J Crit Care; 2018 Dec; 48():183-190. PubMed ID: 30218958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling the effects of 4-factor prothrombin complex concentrate for the management of factor Xa-associated bleeding.
    Muir I; Herzog E; Brechmann M; Ghobrial O; Rezvani Sharif A; Hoffman M
    PLoS One; 2024; 19(9):e0310883. PubMed ID: 39331637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes Associated With 4-Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients.
    Highsmith EA; Morton C; Varnado S; Donahue KR; Sulhan S; Lista A
    J Clin Pharmacol; 2021 May; 61(5):598-605. PubMed ID: 33094836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 4-factor PCC reversal of apixaban and rivaroxaban versus warfarin for intracranial hemorrhage.
    Pasciolla S; Wojcik K; Kavi T; Green D; Shaikh H; Jankowitz B; Igneri LA
    J Thromb Thrombolysis; 2022 Jul; 54(1):74-81. PubMed ID: 34837144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.